Latest news with #CD&R
Tahya Masr
06-05-2025
- Business
- Tahya Masr
Opella launches as an independent company to redefine the future of self-care
It is official: Opella is now a standalone company. Sanofi announced today the closing of the sale to CD&R of a 50.0% controlling stake of Opella, Sanofi keeping a significant shareholding with a 48.2% stake and Bpifrance owning a 1.8% stake. Opella is stepping into its next chapter with powerful backing, and a clear mission - 'Health in Your Hands' - making self-care as simple as it should be. This is not just a change of ownership. This is a bold move. As the third-largest global player in the €190 billion Over-The-Counter and Vitamins, Minerals and Supplements space, Opella starts a new journey in one of the most dynamic, resilient corners of healthcare – where megatrends like aging populations, digital access, and self-care demand are rewriting the rulebook. Opella is headquartered in France but thinks global. Its 100 brands – including Telfast, Doliprane, Bronchicum, Enterogermina, Maalox, Nasacort, Maxilase, Bisolvon and Buscopan – are already trusted names in homes around the world. The self-care environment is still far too complex, leaving most people who suffer without treatment. Opella is grounded in science, with deep consumer obsession and a commitment to sustainability, to offer solutions that help people access the care they deserve. Julie Van Ongevalle, Opella President and CEO: 'Going independent is not just a milestone. It is our moment. I am proud of our talented team of 11,000 who made this happen. With the right partners and a sharp focus, we are set to reshape how people everywhere manage their health – simply, confidently, and on their terms.' Feirouz Ellouze, General Manager of Opella AMET Zone (Africa-Middle East-Türkiye) 'At Opella, our mission is to simplify self-care, making it as simple as it should be. We work together with all our stakeholders to enhance health literacy and extend our vision of 'health in your hands'. This new chapter at Opella is dedicated to advancing our journey towards becoming fast-moving consumer healthcare company globally. We firmly believe in our people and their ability to create a lasting legacy in the countries where we operate.' David Taylor takes on the role of Chairman of Opella's Supervisory Board. Former Chairman and CEO of Procter & Gamble, and current Chairman of the Board of Delta and Senior Advisor to CD&R funds, David brings decades of brand experience, people-first leadership, and a deep belief in doing things better. David Taylor, Chairman of Opella's Supervisory Board: 'What drew me to Opella is a mission with meaning, a company with courage, a talented team, and a business ready to break new ground. Opella is not here to tweak the system – but to reimagine it.' The priority is clear: strengthen trusted brands and deepen presence in key markets. The possibilities are endless – from prescription to over-the-counter switches to smart acquisitions and geographic expansion. This is more than independence. It is the freedom to act. The power to simplify. And the drive to redefine the future of self-care.
Mid East Info
05-05-2025
- Business
- Mid East Info
Opella launches as an independent company to redefine the future of self-care. - Middle East Business News and Information
UAE, May 2025 – It is official: Opella is now a standalone company. Sanofi announced today the closing of the sale to CD&R of a 50.0% controlling stake of Opella, Sanofi keeping a significant shareholding with a 48.2% stake and Bpifrance owning a 1.8% stake. Opella is stepping into its next chapter with powerful backing, and a clear mission – 'Health in Your Hands' – making self-care as simple as it should be. This is not just a change of ownership. This is a bold move. As the third-largest global player in the €190 billion Over-The-Counter and Vitamins, Minerals and Supplements space, Opella starts a new journey in one of the most dynamic, resilient corners of healthcare – where megatrends like aging populations, digital access, and self-care demand are rewriting the rulebook. Opella is headquartered in France but thinks global. Its 100 brands – including Telfast , Enterogermina, Dulcolax, Maalox, Buscopan ,Mucosolvan , Bronchicum ,Naselfast and Pharmaton– are already trusted names in homes around the world. The self-care environment is still far too complex, leaving most people who suffer without treatment. Opella is grounded in science, with deep consumer obsession and a commitment to sustainability, to offer solutions that help people access the care they deserve. Julie Van Ongevalle, Opella President and CEO: 'Going independent is not just a milestone. It is our moment. I am proud of our talented team of 11,000 who made this happen. With the right partners and a sharp focus, we are set to reshape how people everywhere manage their health – simply, confidently, and on their terms.' Feirouz Ellouze, General Manager of Opella AMET Zone (Africa-Middle East-Türkiye) 'At Opella, our mission is to simplify self-care, making it as simple as it should be. We work together with all our stakeholders to enhance health literacy and extend our vision of 'health in your hands'. This new chapter at Opella is dedicated to advancing our journey towards becoming fast-moving consumer healthcare company globally. We firmly believe in our people and their ability to create a lasting legacy in the countries where we operate.' David Taylor takes on the role of Chairman of Opella's Supervisory Board. Former Chairman and CEO of Procter & Gamble, and current Chairman of the Board of Delta and Senior Advisor to CD&R funds, David brings decades of brand experience, people-first leadership, and a deep belief in doing things better. David Taylor, Chairman of Opella's Supervisory Board: 'What drew me to Opella is a mission with meaning, a company with courage, a talented team, and a business ready to break new ground. Opella is not here to tweak the system – but to reimagine it.' The priority is clear: strengthen trusted brands and deepen presence in key markets. The possibilities are endless – from prescription to over-the-counter switches to smart acquisitions and geographic expansion. This is more than independence. It is the freedom to act. The power to simplify. And the drive to redefine the future of self-care. About Opella. Opella is the self-care challenger with the third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people's hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission is our 100 loved brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world's most loved brands, including Telfast , Enterogermina, Dulcolax, Maalox, Buscopan ,Mucosolvan , Bronchicum ,Naselfast, Pharmaton. B Corp certified in multiple markets, we are active players in the journey towards healthier people and planet.
Yahoo
30-04-2025
- Business
- Yahoo
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi retains a significant shareholding of Opella with a 48.2% stake. Bpifrance will own a 1.8% stake in Opella and will join the Board. The transaction was completed on the terms previously disclosed. Sanofi has received total net cash proceeds of around €10 billion. Sanofi is now a pure-play biopharma, strategically focused on pushing the boundaries of science and leveraging cutting-edge research to deliver breakthrough medicines and vaccines. Chief Executive Officer, Sanofi 'We have full confidence in Opella's future as a new independent champion. Built on the strength of its talented teams, deep consumer understanding, and international reach, Opella is perfectly positioned for long-term success. With the support of CD&R—renowned for its expertise in the consumer and healthcare sectors and its commitment to people, communities, and sustainability, Opella is ready to grow and thrive. This new chapter marks the beginning of a promising journey for a company we believe in deeply.' Partner and Head of European Healthcare, CD&R 'This is an exciting opportunity for CD&R to support Opella in building a French headquartered, global consumer health champion. Opella stands out through the strength of its brands and the expertise of its people. CD&R brings complementary experience in the consumer health sector, along with operational insight and long-term capital, to help accelerate Opella's growth. We are committed to supporting Opella's continued development, both in France and abroad and to better serving employees, consumers, and patients alike.' President and Chief Executive Officer, Opella 'Reaching this milestone is an exciting moment in Opella's journey. Through significant transformations, we have become one of the largest global players in our sector, bringing innovation to over half a billion consumers worldwide. We are ready to unlock Opella's full potential, drive value creation, and leverage our teams' exceptional talent to become a leader in the fast-moving consumer healthcare space.' Headquartered in France, Opella employs over 11,000 talented and passionate people, operates in 100 countries with 13 best-in-class and strategic manufacturing sites and four science and innovation development centers. With a portfolio of iconic brands, such as Allegra, Doliprane, and Dulcolax, Opella is already the third-largest business worldwide in the over-the-counter and vitamins, minerals & supplements market (OTC & VMS), serving more than half a billion consumers worldwide. Opella operates in a fast-growing industry driven by sustainable long-term trends, such as an aging population, rising income levels, and greater health and well-being awareness. About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Victor Rouault | +33 6 70 93 71 40 | Léo Le Bourhis | +33 6 75 06 43 81 | Léa Ubaldi | +33 6 30 19 66 46 | Evan Berland | +1 215 432 0234 | Gilbert | +1 516 521 2929 | Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Tarik Elgoutni | +1 617 710 3587 | Châtelet | +33 6 80 80 89 90 | Li | +33 6 84 00 90 72 | Forward-looking statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, business transformations, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans', 'potential', 'outlook', 'guidance' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, those inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. More specifically regarding the transaction described above, these risks and uncertainties include among other things the possibility that the expected strategic benefits, synergies or opportunities from the transaction may not be realized, or may take longer to realize than expected, or potential adverse reactions to the proposed transaction by customers, suppliers, strategic partners or key Sanofi or Opella employees. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Opella group. Attachment Press_ReleaseSign in to access your portfolio
Zawya
25-04-2025
- Business
- Zawya
Clarivate's IP unit draws private equity interest, sources say
LONDON/NEW YORK - CD&R and Nordic Capital are among private equity groups weighing possible bids for Clarivate's intellectual property (IP) unit, two people with knowledge of the matter told Reuters. Clarivate, which has headquarters in London, said in February it was exploring strategic alternatives including potential divestments as part of plans to create value for shareholders, and had appointed Morgan Stanley and Moelis & Company as financial advisers. The New York-listed information group has been holding conversations with bidders about its IP unit and invited them last month to submit indications of interest, the people said, speaking on condition of anonymity because the matter is private. The two private equity funds were among those that submitted expressions of interest, the people said. The sources cautioned that no deal was guaranteed and Clarivate may decide to focus on other divestitures if offers for its IP unit are not eventually high enough. Spokespeople for Clarivate, CD&R and Nordic Capital declined to comment. The plans come after Clarivate's shares have fallen 90% from a high in 2021 as it struggles with organic growth and customer retention. Revenue at the group was $2.56 billion in 2024, compared to $2.63 billion a year earlier, while earnings before interest, tax, depreciation and amortisation (EBITDA) narrowed to $1 billion from $1.12 billion a year earlier, according to its latest annual report. Clarivate, which has an enterprise value of $6.6 billion according to LSEG data, is hoping for a valuation north of $4 billion for the IP assets, the two people and a third one said. However, certain prospective bidders believe the IP unit may be worth less, the people said. EBITDA at Clarivate's IP unit fell by 10.5% to $358 million for the year ending December 2024, partly driven by lower subscription revenues and a decline in renewal volumes, according to its latest annual report. Nordic Capital has been considering buying the IP unit via Anaqua, the IP software business it acquired last November for $2.5 billion, the people said. Anaqua did not respond to requests for comment. Clarivate's top shareholder is private equity firm Leonard Green & Partners with a 16.9% stake, followed by Clarkston Capital Partners with 10% and Italy's Agnelli family with 9.7%, according to LSEG data. Clarivate's IP business, previously called CPA Global, offers software and services that manage patents, trademarks and contracts for law firms and corporations. It also provides the Derwent World Patents Index (DWPI) database, which contains patent applications and grants from patent issuing authorities. Clarivate agreed to combine with the business in 2020 in a $6.8 billion deal. (Reporting by Amy-Jo Crowley in London and Milana Vinn in New York; Editing by Anousha Sakoui and Susan Fenton)
Yahoo
31-03-2025
- Business
- Yahoo
Buyout Firm CD&R Hires Ex-Schwab CEO Bettinger as Senior Adviser
(Bloomberg) -- Clayton Dubilier & Rice has hired Walt Bettinger, the former chief executive officer of Charles Schwab Corp., as one of Wall Street's oldest private equity firms continues to tap the expertise of veteran business leaders. Gold-Rush Fever Returns to Historic New Zealand Mining Town What Frank Lloyd Wright Learned From the Desert Bank Regulators Fight for Desks as OCC Returns to New York Tower These US Bridges Face High Risk of Catastrophic Ship Strikes Charter Schools, Colleges Push Muni Debt Distress Near Record Bettinger, who left Charles Schwab last year after leading it for more than 15 years, will join CD&R as a senior adviser. He's tasked with helping to identify investment opportunities in the financial services and technology sector for CD&R, he said in an interview. 'What appealed to me was the firm's focus on operational excellence,' Bettinger said. 'The fact that around 80% of the value that the firm has generated over the years has been through operational improvement, is quite distinct.' Bettinger will continue to serve on Schwab's board of directors as executive co-chairman. The firm's namesake, Charles 'Chuck' Schwab, is the other co-chairman. CD&R, which was established in 1978, has been hunting for deals after raising a record $26 billion buyout fund in 2023. Unlike some of its peers who are branching out to other areas like private credit and infrastructure, the firm has stuck with its focus on buyout transactions. Last year, CD&R agreed to buy a controlling stake in Sanofi SA's consumer health unit, in a deal that valued the business at about €16 billion ($17 billion). It also teamed up with Stone Point Capital to buy Truist Financial Corp.'s insurance brokerage unit in a deal valuing the business at $15.5 billion. The insurance, wealth and retirement sectors are the focus for CD&R's financial services vertical, according to David Winokur, who joined CD&R as a partner in 2022 to establish and build that business. 'Given the massive wealth transfer that is taking place and the accumulation of wealth in an aging society, this is going to be a key area for us to invest in,' Winokur said. 'The technology sector is increasingly entrenched with financial services, and there is still a tremendous opportunity to use technology to enhance value in the industry.' At CD&R, Bettinger will be part of a senior adviser cohort that includes James McNerney, the former CEO of Boeing Co. and 3M Co., as well as the former head of UK supermarket chain Tesco Plc, Terence Leahy. The buyout firm also has a roster of former senior business executives who help to improve the operational performance of the companies that it owns. 'Over the last 10 to 15 years, we have made a major push into investing in sectors like financial services, technology and tech-enabled services,' Winokur said. 'It's important for us that our senior advisers talent reflects individuals with deep experience and expertise in that space.' Trump's IRS Cuts Are Tempting Taxpayers to Cheat Google Is Searching for an Answer to ChatGPT Israel Aims to Be the World's Arms Dealer Business Schools Are Back How a US Maker of Rat-Proof Trash Bins Got Boxed in by Trump's Tariffs ©2025 Bloomberg L.P. Sign in to access your portfolio
